Overview

A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole

Status:
Completed

Trial end date:
2012-02-09

Target enrollment:

Participant gender:

Summary

This is a two part study. Part A of the study will evaluate the metabolites of GSK221149 following single and repeat oral dosing and will also assess the pharmacokinetics of GSK221149 when administered with a potent CYP3A4 inhibitor Ketoconazole. Part B of the study will look at the pharmacokinetics of GSK221149 following a high fat meal.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Ketoconazole